Sugi Predict

Sugi Predict / Compounds / SCHEMBL246756

SCHEMBL246756

SCHEMBL246756

O=[N+]([O-])c1ccc(Br)c2ccncc12

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.58
▸ HTT P42858 5/20 0.58
▸ TDP1 Q9NUW8 3/20 0.58
▸ GAA P10253 1/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ ALDH1A1 P00352 3/20 0.54
▸ LMNA P02545 2/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ POLB P06746 1/20 0.52
▸ AXL P30530 1/20 0.51
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ HIPK2 Q9H2X6 1/20 0.42
▸ CHUK O15111 1/20 0.40
▸ AAK1 Q2M2I8 1/20 0.40
▸ GSK3B P49841 1/20 0.38
▸ HASPIN Q8TF76 1/20 0.38
▸ RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31162406 1.00 MAPT (0.58) MAPTHTTTDP1GAAL3MBTL1
SCHEMBL7106466 0.93 MAPT (0.54) MAPTHTTTDP1GAAL3MBTL1
SCHEMBL31451862 0.93 MAPT (0.54) MAPTHTTTDP1GAAL3MBTL1
SCHEMBL7987246 0.90 MAPT (0.50) MAPTHTTTDP1GAAL3MBTL1
SCHEMBL6212179 0.89 MAPT (0.52) MAPTHTTTDP1GAAL3MBTL1
SCHEMBL11817125 0.87 MAPT (0.64) MAPTHTTTDP1GAAL3MBTL1
SCHEMBL6973083 0.79 MAPT (0.56) MAPTHTTTDP1GAAL3MBTL1
Iodide SCHEMBL11813329 0.78 MAPT (0.55) MAPTHTTTDP1GAAL3MBTL1
SCHEMBL26933026 0.77 MAPT (0.54) MAPTHTTTDP1GAAL3MBTL1
SCHEMBL29890100 0.77 AXL (0.72) MAPTHTTTDP1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1089976-B1 METHOD OF PREPARING 5- OR 8-BROMOISOQUINOLINE DERIVATIVES NEUROSEARCH AS (DK) 2003-09-24 — — EP claimed
US-6500954-B1 ONE POT PROCESS OF BROMINATION AND NITRATION OF ISOQUINOLINE TO PRODUCE SUCH AS 5-BROMO-8-NITROISOQUINOLINE NEUROSEARCH A/S (DK) 2002-12-31 — — US claimed
EP-4387963-B1 PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 REDX PHARMA LTD (GB) 2025-12-24 — — EP disclosed
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof BAUSCH + LOMB IRELAND LIMITED (IE) 2025-10-07 — — US disclosed
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND SHOUYAO HOLDINGS BEIJING CO LTD (CN) 2025-07-10 — — US disclosed
EP-4055014-B1 PYRROLIDINE AND PIPERIDINE COMPOUNDS YUHAN CORP (KR) 2025-04-30 — — EP disclosed
EP-4501912-A1 NOVEL HETEROCYCLIC COMPOUND Shouyao Holdings (Beijing) Co., Ltd. (CN) 2025-02-05 — — EP disclosed
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 — — EP disclosed
US-20240308965-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2024-09-19 — — US disclosed
CN-118475560-A Novel heterocyclic compound 首药控股(北京)股份有限公司 2024-08-09 — — CN disclosed
CN-114867719-B Pyrrolidine and piperidine compounds 柳韩洋行 2024-06-25 — — CN disclosed
EP-0781284-A1 INDOLE-2,3-DIONE-3-OXIME DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 1997-07-02 — — EP disclosed
WO-1996008495-A1 FUSED INDOLE AND QUINOXALINE DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 1996-03-21 — — WO disclosed
WO-1996008494-A1 INDOLE-2,3-DIONE-3-OXIME DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 1996-03-21 — — WO disclosed
EP-0698025-A1 AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH NEUROSEARCH A/S (DK) 1996-02-28 — — EP disclosed
EP-0664807-A1 QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS. WARNER LAMBERT CO (US) 1995-08-02 — — EP disclosed
US-5436250-A Isatineoxime derivatives, their preparation and use NEUROSEARCH A/S (DK) 1995-07-25 — — US disclosed
EP-0633262-A1 Novel isatineoxime derivatives, their preparation and use NEUROSEARCH A/S (DK) 1995-01-11 — — EP disclosed
WO-1994026747-A1 AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH NEUROSEARCH A/S (DK) 1994-11-24 — — WO disclosed
WO-1994009000-A1 QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1994-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof TRPV1, TRPV3, TRPV2 MAPT 1757/4885HTT 3004/4885TDP1 3629/4885
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND MAPT, MNAT1, MAT2A MAPT 1/4885HTT 17/4885TDP1 1025/4885
US-20240308965-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF TRPV1, TRPV3, TRPV2 MAPT 1757/4885HTT 3004/4885TDP1 3629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.